Tag: Cancer Drugs

Innovent & Shenogen to Evaluate Combo for the Treatment of Patients with Advanced Cancer

drug-development
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced the signing of a collaboration agreement with Shenogen Pharma Group...

FDA Granted Approval to Daiichi Sankyo’s Turalio

The U.S. Food and Drug Administration granted approval to Turalio (pexidartinib) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with seve...

Mylan & Biocon Launched Ogivri™, a Biosimilar to Herceptin®, in Australia

Biocon Ltd. and Mylan N.V. announced the launch in Australia of Ogivri™ (trastuzumab), a biosimilar to Herceptin® (trastuzumab), for the treatment of HER2-overexpressing breast cancer and metastatic s...

Alligator Bioscience Regained Exclusive Rights for CD40 from Janssen Biotech

Alligator Bioscience announced that it has regained exclusive, worldwide rights from Janssen Biotech Inc. to develop and commercialize the CD40 agonistic antibody, ADC-1013 (JNJ-64457107), its lead tu...

AstraZeneca’s Lynparza to be Funded through UK’s Cancer Drugs Fund

astrazeneca
A "game-changing" ovarian cancer drug that can extend lives by delaying or even preventing the disease recurring is now being made available on the NHS. Lymparza (olaparib) could offer a cure for some...

FDA Approved RUXIENCE™ for the Treatment of Patients with non-Hodgkin’s Lymphoma

pfizer
Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved RUXIENCE™ (rituximab-pvvr), a biosimilar to Rituxan® (rituximab), for the treatment of adult patients wit...

Anixa Biosciences to Develop Innovative Breast Cancer Vaccine Technology with Cleveland Clinic

cancer treatment
Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body's immune system to fight cancer, announced that it has established a strategic alliance and license agreement with Cleve...

GlobalData Forecast: B-cell NHL Market Will Reach $9.2bn by 2027

The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets at a compound annual growth rate (CAGR) of 4.9%, according to Gl...

IBTC Announced Partnership with Karyopharm to Accelerate Treatment of Brain Cancer

cancer drugs
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics to accelerate the treatment of brain cancer. The Ivy Brain Tumor Center will em...

SMC Recommended Janssen’s Darzalex for Multiple Myeloma Treatment

The Scottish Medicines Consortium (SMC) has recommended Darzalex® (daratumumab) plus bortezomib and dexamethasone as an option for treating relapsed multiple myeloma in people who have had only one pr...

FDA Granted Accelerated Approval to Xpovio Tablets

The U.S. Food and Drug Administration granted accelerated approval to Xpovio (selinexor) tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed ...

Nativita Invested $10 mln in Cancer Drugs Production

Another $10 million of investment is to be injected in the state-of-the-art production of cancer drugs by Nativita. The matter was discussed at the meeting of Chairman of the Council of the Republic o...

CHMP Recommended Roche’s Tecentriq for Treatment of Metastatic Triple-Negative Breast Cancer

Roche announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane®;...

FDA Approved DARZALEX® for Newly Diagnosed Patients with Multiple Myeloma

janssen
The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethaso...

Eisai Achieved Total Synthesis of Novel Anticancer Drug

Eisai Co., Ltd. announced that a joint research group including scientists from Eisai and Professor Yoshito Kishi’s group of Harvard University has achieved a total synthesis and obtained results of n...

Gilead Sciences Unite with Nurix to Develop Innovative Cancer Drugs

Gilead Sciences, Inc. and Nurix Therapeutics, Inc., a company discovering drugs that harness the body’s natural process to control protein levels, announced a global strategic collaboration to discove...